Skip to main content
Retour
TSMRF logo

Tsumura & Co.

Qualité des données : 100%
Suracheté
TSMRF
OTC Healthcare Drug Manufacturers - Specialty & Generic
23,20 €
0,00 € (0,00%)
Cap. Boursière : 1,72B
Fourchette du Jour
23,20 € 28,15 €
Fourchette 52 Semaines
23,20 € 28,15 €
Volume
100
Moyenne 50J / 200J
23,20 € / 23,55 €
Clôture Précédente
23,20 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 0,1 0,4
P/B 0,0 2,9
ROE % 11,4 3,7
Net Margin % 17,9 3,8
Rev Growth 5Y % 11,7 10,0
D/E 0,2 0,2

Points Clés

Revenue grew 11,68% annually over 5 years — strong growth
Earnings grew 94,10% over the past year
ROE of 11,35% — decent returns on equity
Net margin of 17,91% shows strong profitability
Debt/Equity of 0,23 — conservative balance sheet
Generating 4,03B in free cash flow

Croissance

Revenue Growth (5Y)
11,68%
Revenue (1Y)20,05%
Earnings (1Y)94,10%
FCF Growth (3Y)51,99%

Qualité

Return on Equity
11,35%
ROIC8,11%
Net Margin17,91%
Op. Margin22,16%

Sécurité

Debt / Equity
0,23
Current Ratio4,78
Interest Coverage77,46

Valorisation

P/E Ratio
0,05
P/B Ratio0,01
EV/EBITDA-0,03
Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 20,05% Revenue Growth (3Y) 13,72%
Earnings Growth (1Y) 94,10% Earnings Growth (3Y) 40,27%
Revenue Growth (5Y) 11,68% Earnings Growth (5Y) 20,60%
Profitability
Revenue (TTM) 181,09B Net Income (TTM) 32,43B
ROE 11,35% ROA 6,98%
Gross Margin 50,02% Operating Margin 22,16%
Net Margin 17,91% Free Cash Flow (TTM) 4,03B
ROIC 8,11% FCF Growth (3Y) 51,99%
Safety
Debt / Equity 0,23 Current Ratio 4,78
Interest Coverage 77,46 Dividend Yield 0,03%
Valuation
P/E Ratio 0,05 P/B Ratio 0,01
P/S Ratio 0,01 PEG Ratio 0,10
EV/EBITDA -0,03 Dividend Yield 0,03%
Market Cap 1,72B Enterprise Value -1,17B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 181,09B 150,85B 140,04B 129,55B 116,41B
Net Income 32,43B 16,71B 16,48B 18,84B 15,33B
EPS (Diluted) 427,15 219,82 215,63 246,21 200,40
Gross Profit 90,58B 68,82B 68,28B 66,47B 60,46B
Operating Income 40,13B 20,02B 20,92B 22,38B 19,38B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 464,38B 428,25B 396,81B 350,98B 319,06B
Total Liabilities 134,27B 132,89B 124,57B 92,87B 85,89B
Shareholders' Equity 300,53B 270,80B 252,05B 239,77B 217,79B
Total Debt 70,34B 79,69B 79,69B 49,69B 52,85B
Cash & Equivalents 73,23B 78,08B 94,75B 67,55B 61,31B
Current Assets 295,71B 281,29B 268,32B 229,42B 204,27B
Current Liabilities 61,91B 68,56B 47,21B 45,88B 48,38B

Scores de Stratégies

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#168 of 820
58
Growth Price/Sales Ratio Focus (Ken Fisher)
#448 of 616
20
Value Defensive Investing (Benjamin Graham)
#306 of 708
32

Activité Récente

Entré Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entré Defensive Investing (Benjamin Graham)
Mar 24, 2026